Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.

Nature cancer·2026

Same author

Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma.

Current oncology reports·2026

Same author

Mutational landscapes of brain metastases across various histological subtypes of lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026

Same author

Prospects for implementing the European Code of Cancer Practice: Lessons from Poland.

Health policy (Amsterdam, Netherlands)·2026

Same author

Polish consensus on smoking cessation intervention within lung cancer screening 1.

Archives of medical science : AMS·2026

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Intergroup Exemestane Study mature analysis: overall survival data.

Jacek Jassem¹,

¹Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland.

Anti-Cancer Drugs

|June 24, 2008

Summary

Switching to exemestane, an aromatase inhibitor, after 2-3 years of tamoxifen improves survival for women with oestrogen receptor-positive breast cancer compared to continuing tamoxifen therapy.

More Related Videos

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Related Experiment Videos

Last Updated: Jul 6, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Area of Science:

Oncology
Endocrinology
Pharmacology

Background:

Standard adjuvant endocrine therapy for oestrogen receptor-positive breast cancer involves 5 years of tamoxifen.
Emerging evidence suggests alternative treatment strategies may improve patient outcomes.

Purpose of the Study:

To evaluate the efficacy of switching to an aromatase inhibitor (AI) after initial tamoxifen therapy.
To compare survival rates between patients continuing tamoxifen and those switching to an AI.

Main Methods:

The Intergroup Exemestane Study (IES) involved postmenopausal women with early-stage, oestrogen receptor-positive breast cancer.
Participants received 2-3 years of tamoxifen, followed by either exemestane or continued tamoxifen for a total of 5 years of endocrine therapy.

Main Results:

Switching to exemestane after 2-3 years of tamoxifen significantly improved survival compared to continuing tamoxifen therapy.
The findings support the use of aromatase inhibitors in adjuvant endocrine therapy for breast cancer.

Conclusions:

Switching from tamoxifen to an aromatase inhibitor like exemestane after 2-3 years is a superior adjuvant endocrine therapy strategy.
This approach offers improved survival benefits for postmenopausal women with oestrogen receptor-positive breast cancer.